Therapy for neurocysticercosis (Q36107278)

12 August 2017

1 reference

title

Therapy for neurocysticercosis (English)

1 reference

12 August 2017

1 reference

Osvaldo Massaiti Takayanagui

series ordinal

1

1 reference

12 August 2017

1 January 2004

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

1

1 reference

12 August 2017

129-139

1 reference

Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management.

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Taenia solium cysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Proposed diagnostic criteria for neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Neurocysticercosis: a major cause of neurological disease worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Current consensus guidelines for treatment of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Pharmacokinetic optimisation of the treatment of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Short regimen of praziquantel in the treatment of single brain enhancing lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Optimization of the single-day praziquantel therapy for neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Large cerebral infarction during praziquantel therapy in neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Management of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Cysticercosis and epilepsy: a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Human case management and treatment of cysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

High prevalence of calcified silent neurocysticercosis in a rural village of Mexico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Neurocysticercosis: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Controversies in the management of cysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Bioavailability of praziquantel increases with concomitant administration of food

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

The penetration of anti-infectives into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

Neurocysticercosis: eradication of cysticercosis is an attainable goal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.129

21 January 2018

Identifiers

DOI

10.1586/14737175.4.1.129

1 reference

12 August 2017

1 reference

PubMed ID

15853623